You are here
Therapeutic Considerations in Advanced Renal Cell Carcinoma: A Continuum of Care
Fri 25 Sept / 14:00 - 16:00 / Hall A5
Prognostic markers for renal cell carcinoma (RCC) can support patient counseling and trial design; however, there are currently no predictive markers to guide therapy selection. Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for first-line treatment of advanced RCC have comparable efficacy, making tolerability and patient preference important factors. In the PISCES study, patients preferred pazopanib over sunitinib in this setting. The choice between everolimus and axitinib following prior VEGFR TKI should consider efficacy and potential for cumulative toxicity.
This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.
B. Escudier (France)
Bernard Escudier introduces the Symposium, which aims to discuss therapeutic decisions across the continuum of care in kidney cancer.
D. Heng (Canada)
Daniel Heng talks about treatment choices in advanced renal cell carcinoma, considering prognostic scoring, efficacy and safety in everyday practice.
S. Osanto (Netherlands)
Bernard Escudier presents a case study. Susanne Osanto looks at the process of selecting an RCC therapy, and the differences between pazopanib and sunitinib, noting that patient preference is an important consideration.
E. Calvo (Spain)
Emiliano Calvo, who was part of the RECORD-1 trial, talks about the second-line options for patients with advanced kidney cancer. He reviews data from clinical trials including RECORD-1, RECORD-4 and AXIS.
B. Escudier (France)
Bernard Escudier leads a panel discussion on therapeutic decisions across the continuum of care in kidney cancer with Daniel Heng, Susanne Osanto and Emiliano Calvo to conclude the Symposium.